Journal Article

AtopyReg®, the Prospective Italian Patient Registry for Moderate-to-Severe Atopic Dermatitis in Adults: Baseline Demographics, Disease Characteristics, Comorbidities, and Treatment History

Hansel, Katharina, Napolitano, Maddalena, Schettini, Natale, Argenziano, Giuseppe, Tonini, Giulia, Corazza, Monica, Patruno, Cataldo, Schena, Donatella, Chiricozzi, Andrea, Rossi, Mariateresa, Passante, Maria, Stingeni, Luca, Romanelli, Marco, Calzavara-Pinton, Piergiacomo, Marietti, Rossella, Casciola, Gabriele, Pigatto, Paolo D., Girolomoni, Giampiero, Fabbrocini, Gabriella, Peris, Ketty, Fargnoli, Maria C., Ferrucci, Silvia M., Marzano, Angelo V., Romita, Paolo, Esposito, Maria, Foti, Caterina

2024

Overview

Background and Objective AtopyReg ® is a multicenter, prospective, observational, non-profit cohort study on moderate-to-severe atopic dermatitis in adults promoted in 2018 by the Italian Society of Dermatology and Venereology (SIDeMaST). We aimed to describe baseline demographics, disease characteristics, comorbidities, and therapeutic data of adult patients affected by moderate-to-severe atopic dermatitis. Methods Patients were selected based on the following inclusion criteria: age ≥ 18 years; Eczema Area and Severity Index score ≥ 16 or localization in visible or sensitive areas (face, neck, hands, or genitalia), or a Numeric Rating Scale itch score ≥ 7 or a Numeric Rating Scale sleep loss score ≥ 7, or a Dermatology Life Quality Index score ≥ 10. Demographic and clinical data at baseline were recorded and analyzed. Results A total of 1170 patients (male 51.1%; mean age: 44.7 years; range 18–90 years) were enrolled by 12 Italian Dermatology Units between January 2019 and November 2022. Skin lesions were eczematous in 83.2% of patients, the most involved site were the flexures (53.9%), face (50.9%), and neck (48.0%). Mean Eczema Area and Severity Index score was 22.3, mean Dermatology Life Quality Index value was 17.6, mean Patient Oriented Eczema Measure score was 13.1, and mean Numeric Rating Scale itch and sleep loss scores were 7.6 and 5.9, respectively. Previous systemic therapies were corticosteroids in 77.7% of patients, antihistamines in 50.3% of patients, and cyclosporine A in 42.6% of patients. Conclusions This baseline data analysis deriving from AtopyReg ® provides real-life evidence on patients with moderate-to-severe atopic dermatitis in Italy confirming the high burden of atopic dermatitis with a significant impact on patients’ quality of life.

• Publisher: Springer International Publishing,Springer Nature B.V
• Subject: Adults / Age / Alcohol / Asthma / Body mass index / Clinical trials / Comorbidity / Cytokines / Data collection / Demographics / Dermatitis / Dermatology / Eczema / Education / Enrollments / Food allergies / Localization / Medicine / Medicine & Public Health / Original Research Article / Patients / Pharmacology/Toxicology / Pharmacotherapy / Quality of life / Rhinitis / Secondary education / Self report / Sleep deprivation